What Is ED3?
Deerfield Management Company, a healthcare investment firm and Empire Discovery Institute have formed a translational research partnership called ED3. Through this partnership, Deerfield has allocated up to $65M to accelerate the development of novel therapeutics.
ED3 funding and support is available for projects in high-need therapeutic areas, as well as those targeting patients suffering from hard-to-treat and rare diseases.
General Inquiries
ED3 is accepting general inquiries and letters of intent from research investigators at the University of Rochester and the University at Buffalo. Interested parties should contact their local Technology Transfer Office about their interest in ED3 and to verify that their program is available for licensing.
For more information,
Molly Mesko, MBA
Director of Portfolio Development and Alliance Management
E-mail: meskom@discoverEDl.org
Our Values
1. Innovation
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla facilisi. Fusce varius, arcu et faucibus tincidunt, nunc sapien volutpat tortor, eget dapibus odio odio in justo.
2. Collaboration
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla facilisi. Fusce varius, arcu et faucibus tincidunt, nunc sapien volutpat tortor, eget dapibus odio odio in justo.
3. impact
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla facilisi. Fusce varius, arcu et faucibus tincidunt, nunc sapien volutpat tortor, eget dapibus odio odio in justo.
What We Do
Target to hit
HIT TO LEAD
Lead Optimization
Pre-Clinical
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla facilisi. Fusce varius, arcu et faucibus tincidunt, nunc sapien volutpat tortor, eget dapibus odio odio in justo. Sed eget massa eu augue sodales sodales. Suspendisse potenti.
Donec sagittis eros et velit fermentum, at tincidunt felis bibendum. Etiam in orci et ligula tincidunt tincidunt. Duis posuere, libero vel malesuada consequat, felis eros cursus eros, non cursus nisi arcu vel risus.